Prazepam

DB01588ApprovedIllicitSmall molecule

Prazepam is a benzodiazepine used to manage more severe forms of anxiety disorders. It is a schedule IV drug in the U.S.

Mechanism: Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
Curator reviewed
Primary indication: For the treatment of anxiety disorders.Curator reviewed · 3 structured indications
Formula / weight: C₁₉H₁₇ClN₂O · 324.804 g/mol (avg)
Code names: W 4020

Resolves to

Compound

UNIIQ30VCC064MCAS2955-38-6ChEMBLCHEMBL969ChEBI8362PubChem4890KEGGD00470

Clinical / RWD

RxNorm8627ATCN05BA11PharmGKBPA164776668

Structure

InChIKeyMWQCHHACWWAQLJ-UHFFFAOYSA-NSMILESClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1

Targets

P30536TSPO

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

803Drug interactionsStructured to mechanism, not free text

3Structured indicationsCondition, population, route and combination as fields, not prose

7ContraindicationsEach with its own population and attribute set

18Marketed productsAcross 2 countries and 7 labellers

1ATC codeIncluding every combination product, plus 17 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prazepam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In